Who
Michael Castagna
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, MannKind.
In numbers
- Trades disclosed
- 148
- Buys
- 22
- Sells
- 22
- Bought
- $918K
- Sold
- $4.5M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 17 May 2016
- Last trade
- 15 Jul 2026
- Last filed
- 17 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Jul 2026filed 17 Jul 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Code M | —350,260 at $0.00 | filing |
| 15 Jul 2026filed 17 Jul 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Code F | $789K192,819 at $4.09 | filing |
| 15 Jul 2026filed 17 Jul 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Code F | $194K47,481 at $4.09 | filing |
| 15 Jul 2026filed 17 Jul 2026 | MNKD MannKindoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —350,260 at $0.00 | filing |
| 15 Jul 2026filed 17 Jul 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Code F | $262K63,996 at $4.09 | filing |
| 15 Jul 2026filed 17 Jul 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Code F | $241K58,904 at $4.09 | filing |
| 15 Jul 2026filed 17 Jul 2026 | MNKD MannKindoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —350,260 at $0.00 | filing |
| 15 Jul 2026filed 17 Jul 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Code M | —350,260 at $0.00 | filing |
| 15 Jul 2026filed 17 Jul 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Code F | $789K192,819 at $4.09 | filing |
| 15 Jul 2026filed 17 Jul 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Code F | $194K47,481 at $4.09 | filing |
| 15 Jul 2026filed 17 Jul 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Code F | $262K63,996 at $4.09 | filing |
| 15 Jul 2026filed 17 Jul 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Code F | $241K58,904 at $4.09 | filing |
| 11 May 2026filed 13 May 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Code F | $123K34,957 at $3.52 | filing |
| 11 May 2026filed 13 May 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Code F | $123K34,957 at $3.52 | filing |
| 23 Mar 2026filed 25 Mar 2026 | MNKD MannKindoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —796,000 at $0.00 | filing |
| 23 Mar 2026filed 25 Mar 2026 | MNKD MannKindoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —782,000 at $0.00 | filing |
| 23 Mar 2026filed 25 Mar 2026 | MNKD MannKindoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —796,000 at $0.00 | filing |
| 23 Mar 2026filed 25 Mar 2026 | MNKD MannKindoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —782,000 at $0.00 | filing |
| 10 Mar 2026filed 10 Mar 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Bought | $259K100,000 at $2.59 | filing |
| 10 Mar 2026filed 10 Mar 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Bought | $259K100,000 at $2.59 | filing |
News
Comparing MannKind (NASDAQ:MNKD) & Iovance Biotherapeutics (NASDAQ:IOVA)MNKD · tickerreport.com · 15 Oct 2026MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)MNKD · manilatimes.net · 10 Oct 2026
0 headlines in the last 90 days name Michael Castagna; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.